Home › Trial NCT06446570
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
- Trial IDNCT06446570
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorSeoul National University Hospital
- Enrollment18
- Start date2017-09-10
- ConditionsHNSCC · Head and Neck Neoplasms
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.